Recalls
Searchable archive of product recalls from the FDA, USDA FSIS, CPSC, NHTSA, and EPA — translated into plain English, severity-scored from objective criteria, and always linked back to the original government notice.
Every recall on this list has been scored 1–5 against an objective rubric from the agency’s own classification, presence of reported injuries or deaths, distribution scope, and hazard type. The colored severity badge on each card is the score — 5 (Critical) means deaths or serious injuries are reported, 4 (Severe) means significant injury or hospitalization risk, and 3 (High) means a known hazard with no confirmed harm yet. Filter to 3+ (High and above) if you want to skip routine Class-III notices.
The agency chips above control which streams are visible. FDA spans food, drugs, and medical devices. USDA FSIS is meat, poultry, and processed egg products. CPSC is household consumer products. NHTSA is vehicles, tires, and child seats. Nationwide on a card means the recall affects every US state — most do — while a state list means distribution was limited.
Click any recall to see the full summary, affected lot codes and model numbers, the agency’s own classification, and a direct link back to the original government notice for verification.
Minimum severity
Assurance Infusion is recalling specific lots of Morphine 30mg/mL injection syringes due to a lack of sterility assurance. The affected products were distributed nationwide.
Assurance Infusion is recalling specific lots of Buprenorphine and Morphine injection due to a lack of sterility assurance. The affected product was distributed nationwide.
Assurance Infusion is recalling specific lots of multi-drug injection syringes because of a lack of sterility assurance.
Assurance Infusion is recalling BUP 4MG/FENT 3000MCG/ML Injection in 20 mL syringes due to a lack of sterility assurance.
Assurance Infusion is recalling specific lots of Ipamorelin 2000mcg/mL injections because they may lack sterility assurance.
Assurance Infusion is recalling BUP 5.3MG/FENT 1050 MCG/ML Injection in 20 mL syringes due to a lack of sterility assurance.
Assurance Infusion is recalling specific lots of TRIMIX injection due to a lack of sterility assurance. The product was distributed nationwide in the United States.
Assurance Infusion is recalling specific lots of Hydromorphone 3mg/mL injection syringes due to a lack of sterility assurance. The products were distributed nationwide.
Assurance Infusion is recalling specific lots of Hydromorphone 5mg/mL injections because they may lack sterility assurance.
Assurance Infusion is recalling specific lots of multi-drug syringes because they may lack sterility assurance. Patients should contact their healthcare provider for guidance.
Assurance Infusion is recalling specific lots of HCG 3000U/1ML injections because they lack sterility assurance. The recall covers products distributed nationwide.
Assurance Infusion is recalling BUP 20MG/SUF 105MCG/ML Injection in 20 mL syringes due to a lack of sterility assurance. The recall is nationwide.
Assurance Infusion is recalling Morphine Sulfate Injection in 20 mL syringes due to a lack of sterility assurance. The product was distributed nationwide.
Assurance Infusion is recalling a specific lot of buprenorphine and fentanyl injection due to a lack of sterility assurance. The product was distributed nationwide.
Assurance Infusion is recalling BPC-157 vials nationwide because the product lacks sterility assurance.
Assurance Infusion is recalling specific lots of Baclofen and Hydromorphone injection due to a lack of sterility assurance.
Glenmark Pharmaceuticals is recalling Ranitidine Tablets USP 300 mg because the FDA detected the NDMA impurity in the product.
Asclemed USA Inc. dba Enovachem Pharmaceuticals is recalling Estriol, USP, (Micronized), 0.06 g, due to out-of-specification impurity test results.
Appco Pharma LLC is recalling specific lots of Ranitidine Capsules 150 mg because the active ingredient contained the impurity N-nitrosodimethylamine (NDMA).
Glenmark Pharmaceuticals is recalling Ranitidine Tablets USP 300 mg because the FDA detected the NDMA impurity in the product.
Glenmark Pharmaceuticals is recalling 217,956 bottles of Ranitidine Tablets USP 150 mg nationwide because the product contains the NDMA impurity.
Glenmark Pharmaceuticals is recalling Ranitidine Tablets USP 300 mg because of the presence of the NDMA impurity.
AAA Pharmaceutical is recalling specific lots of Ranitidine 150 mg tablets because the active ingredient contained the impurity N-nitrosodimethylamine (NDMA).
AAA Pharmaceutical is recalling Ranitidine 150 mg tablets because the active ingredient contained the impurity N-nitrosodimethylamine (NDMA).
Glenmark Pharmaceuticals is recalling Ranitidine Tablets USP 150 mg because the product contains the NDMA impurity.